Company intelligence / Profile preview

Fovero Therapeutics

Brisbane, Queensland, Australia

Ownership: Private
Development stage: Other

Overview

Fovero Therapeutics has demonstrated that its lead anti-Galectin‑9 antibody, FT002, achieves complete tumor clearance and durable protection in preclinical models of MSS colorectal cancer and triple-negative breast cancer. The therapy reprograms anti-tumor immunity with a mechanistically distinct approach from other GAL9 antibodies. Their second program, FT024, targets a novel immune pathway for autoimmune/inflammatory disease; both programs are supported by over US$2M in non-dilutive funding and are progressing toward IND-enabling studies expected to begin in late 2025.

Therapeutic areas: ImmunologyOncology
Modalities: AntibodyBiologic
Industry: Biotech

Drug pipeline

1 asset

FT0024

Preclinical

Partnerships

Brandon BioCatalyst (funding partner)U.S. Department of Defense grant support for R&D funding

Beyond the preview

Go deeper on Fovero Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fovero Therapeutics.

Explore the full profile